Mesothelioma Statistics & Survival Rates

Comprehensive mesothelioma statistics including annual diagnoses, survival rates by stage, and demographic data from CDC, SEER, and NIH sources.

Key Statistics at a Glance

~3,000
Annual U.S. diagnoses
73%
1-year survival rate
12%
5-year survival rate
Key mesothelioma statistics
StatisticValueSource
Annual U.S. diagnoses~3,000CDC/SEER
Global annual cases~30,000WHO
1-year survival rate73%NIH
5-year survival rate12-15%SEER
Average latency period38 yearsCDC
Male-to-female ratio3:1CDC

Annual Incidence

Approximately 3,000 new cases of mesothelioma are diagnosed annually in the United States, representing roughly 1 in 100,000 people. The CDC reported 2,669 new mesothelioma cases in 2022, the most recent year with complete data.

~3,000
U.S. cases per year
~30,000
Global cases per year

Globally, the incidence is substantially higher at approximately 30,000 cases annually, with a global incidence rate of about 0.30 cases per 100,000 people.

U.S. Mesothelioma Deaths (1999-2020)

Mortality Data

Over 54,000 deaths from mesothelioma were reported by the CDC between 1999 and 2020. Projections indicate the absolute peak in pleural mesothelioma mortality occurred during 2020–2024, with an estimated 6,740 deaths (4,946 males and 1,794 females).

Survival Rates by Type

Survival statistics vary significantly between mesothelioma types:

Pleural Mesothelioma (Most Common)

80%
Of all cases
73%
1-year survival
12-15%
5-year survival

Median survival: 12-18 months overall

Peritoneal Mesothelioma

Better Outcomes with HIPEC

Peritoneal mesothelioma has notably better outcomes due to the effectiveness of HIPEC (heated intraperitoneal chemotherapy).

47-52%
5-year survival
4-5 years
Average survival

Survival by Stage at Diagnosis

Survival rates by stage for pleural mesothelioma with multimodal treatment
StageMedian Survival2-Year Survival5-Year Survival
Stage 119-22 months39%11%
Stage 219 months39%
Stage 318 months41%13%
Stage 413-15 months31%11%
Early Detection Impact

Early-stage patients (Stage 1-2) who receive multimodal treatment (surgery, chemotherapy, and immunotherapy) achieve a median survival of 32.1 months — nearly triple the overall median survival.

Demographics

Gender Disparity

3:1
Male to female ratio
75%
Cases are male

Men are nearly 3 times more likely to be diagnosed with mesothelioma than women. This disparity reflects historical patterns of occupational asbestos exposure in male-dominated industries.

Incidence rates at age 75+:

Mesothelioma incidence by gender
GenderIncidence Rate (age 75+)
Men12.4 per 100,000
Women2.7 per 100,000

Age Distribution

Mesothelioma predominantly affects older populations, reflecting the disease’s long latency period:

Mesothelioma incidence by age
Age GroupIncidence Rate (per 100,000)
75+6.7
65+4.4
50-640.7
Under 500.1

Veterans

Veterans at High Risk

Veterans comprise over 30% of mesothelioma cases due to extensive asbestos use in military equipment, shipyards, and facilities through the 1980s.

Stage at Diagnosis

Distribution of mesothelioma diagnoses by stage
Stage at DiagnosisPercentage of Cases
Stage 19%
Stage 214%
Stages 3-465%
Undetermined12%
Late Diagnosis Challenge

The high percentage of late-stage diagnoses reflects the disease’s nonspecific early symptoms and long latency period.

Geographic Distribution

United States

California has the highest number of mesothelioma cases, with over 6,800 residents diagnosed between 1999 and 2019.

Key Facts
Widespread asbestos use across industries
Numerous coastal shipyards
Large population centers
Historical oil refinery and aerospace industry presence

Global Patterns

Key Facts
Europe, Australia, New Zealand, and South Africa have highest diagnosis rates
In Europe, mesothelioma accounted for 40% of occupational cancers (2013-2021)
Great Britain reports ~2,400 mesothelioma deaths annually

Latency Period

38 years
Average latency
10-50
Years range
65+
Peak diagnosis age

The extended latency explains:

  • Why diagnoses peak in the 65+ age group
  • Why cases continue despite reduced asbestos use since the 1980s
  • Why early-life occupational exposure often leads to late-life diagnosis

Chemotherapy

80%
Patients receive chemotherapy
14 mo
Median survival with chemo

The combination of cisplatin and pemetrexed has been the standard first-line treatment for over 15 years.

Cell Type Matters

Patients with epithelioid tumors receiving chemotherapy survived 26.7 months compared to 15 months for non-epithelioid patients.

Immunotherapy

Key Facts
22% reduction in death risk compared to chemotherapy alone (meta-analysis of 2,549 patients)
Chemotherapy + durvalumab increases median survival to 20.4 months

Surgery Eligibility

Only approximately 20% of patients qualify for surgery, which improves outcomes when combined with chemotherapy and immunotherapy.

How many people get mesothelioma each year?

Approximately 3,000 new cases are diagnosed annually in the United States. Globally, about 30,000 cases are diagnosed each year.

What is the survival rate for mesothelioma?

The overall 5-year survival rate is 12-15%. However, peritoneal mesothelioma patients treated with HIPEC achieve 47-52% 5-year survival, and early-stage patients with multimodal treatment achieve 32+ month median survival.

Why are most mesothelioma patients men?

Men comprise about 75% of cases because historically male-dominated industries (shipbuilding, construction, manufacturing) had the highest asbestos exposure.

Are mesothelioma cases declining?

Cases peaked around 2020-2024 and are expected to gradually decline as people exposed during peak asbestos use (1940s-1970s) age. However, cases will continue for decades due to the long latency period.

Statistics are updated annually. Last update: January 2026.